| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 90,039 | 92,904 | ||
| Marketable securities | 36,994 | 64,050 | ||
| Restricted cash | 1,347 | 1,082 | ||
| Accounts receivable, net | 19,703 | 19,649 | ||
| Inventories | 8,341 | 7,128 | ||
| Prepaid expenses and other current assets | 12,122 | 12,055 | ||
| Total current assets | 168,546 | 196,868 | ||
| Property and equipment, gross | 5,208 | - | ||
| Less accumulated depreciation and amortization | 4,513 | - | ||
| Property and equipment, net | 695 | 688 | ||
| Restricted deposit | 177 | 177 | ||
| Right-of-use assets, operating and finance leases | 8,489 | 5,551 | ||
| Marketable securities | 380 | 4,632 | ||
| Other non-current assets | 6,759 | 801 | ||
| Total assets | 185,046 | 208,717 | ||
| Accounts payable and accrued expenses | 26,173 | 30,962 | ||
| Employee related accrued expenses | 11,114 | 11,646 | ||
| Other liabilities, current | 4,957 | 4,940 | ||
| Total current liabilities | 42,244 | 47,548 | ||
| Prepaid forward obligation | 126,067 | 124,833 | ||
| Long-term debt | 122,111 | 122,508 | ||
| Lease, liabilities, noncurrent | 6,241 | 3,413 | ||
| Uncertain tax positions liability | 3,791 | 3,791 | ||
| Total liabilities | 300,454 | 302,093 | ||
| Ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at september 30, 2025 and december 31, 2024 46,781,211 and 42,231,746 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 128 | 126 | ||
| Additional paid-in capital | 817,793 | 806,497 | ||
| Retained Earnings Accumulated Deficit | - | -900,005 | ||
| Accumulated deficit | -933,352 | -900,000 | ||
| Accumulated other comprehensive income | 23 | 6 | ||
| Total shareholders' deficit | -115,408 | -93,376 | ||
| Total liabilities and shareholders' deficit | 185,046 | 208,717 | ||
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)